{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:03Z","timestamp":1790697843905,"version":"4.1.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To describe a case of allergic reaction to intravitreal (IVT) injection of antivascular endothelial growth factor (anti-VEGF) medications in patients with alpha-gal syndrome.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A single case was evaluated.\n                    <jats:bold>Results:<\/jats:bold>\n                    A 57-year-old woman with a known diagnosis of alpha-gal syndrome was evaluated. Clinical presentation, prior treatment history, and response to different anti-VEGF agents were reviewed. The patient presented with worsening vision in her right eye due to a subfoveal choroidal neovascular membrane secondary to neovascular age-related macular degeneration. She had experienced a systemic allergic reaction following an IVT injection of bevacizumab but subsequently tolerated ranibizumab without any adverse effects, resulting in improvement in her vision.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Bevacizumab, aflibercept, and faricimab are recombinant immunoglobulins produced by DNA technology in Chinese hamster ovary cells, which may contain galactose-\u03b1-1,3-galactose (alpha-gal), a potential allergen for patients with alpha-gal syndrome. Patients with alpha-gal syndrome may develop allergic reactions to certain IVT anti-VEGF agents derived from mammalian expression systems. Ranibizumab, produced using an\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    expression and lacking alpha-gal, seems to be a safe and effective option for patients with alpha-gal syndrome requiring IVT anti-VEGF therapy.\n                  <\/jats:p>","DOI":"10.1177\/24741264251400700","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:59:44Z","timestamp":1767085184000},"page":"344-349","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Alpha-Gal Syndrome Allergy to Intravitreal Administration of Antivascular Endothelial Growth Factor Agents"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-1092","authenticated-orcid":false,"given":"Eric","family":"Zhang","sequence":"first","affiliation":[{"name":"Wolfe Eye Clinic, West Des Moines, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Bylund","sequence":"additional","affiliation":[{"name":"Wolfe Eye Clinic, West Des Moines, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pritzker School of Medicine, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Massop","sequence":"additional","affiliation":[{"name":"Wolfe Eye Clinic, West Des Moines, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.12.003"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S265660"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7830"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S276872"},{"key":"e_1_3_3_6_2","first-page":"3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou R","year":"2010","unstructured":"Zhou R, Caspi RR. Ocular immune privilege. F1000Prime Rep. 2010;2:3. doi:10.3410\/B2-3","journal-title":"F1000Prime Rep"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.5301\/EJO.2010.6049"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001493"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000581"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"key":"e_1_3_3_11_2","volume-title":"Response Package Link","author":"Roberson E.","unstructured":"Roberson E. Response Package Link. South San Francisco, CA: Genentech, Inc; 2025."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26960"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.856049"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1110-1153"},{"key":"e_1_3_3_15_2","volume-title":"EYLEA HD (aflibercept) Injection and Cross-Reactivity in Patients with Allergy to Galactose-\u03b1-1, 3 Galactose (\u03b1-Gal)","author":"Tavakoli S","year":"2025","unstructured":"Tavakoli S. EYLEA HD (aflibercept) Injection and Cross-Reactivity in Patients with Allergy to Galactose-\u03b1-1, 3 Galactose (\u03b1-Gal). Tarrytown, NY: Regeneron Pharmeceuticals, Inc; 2025."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.7324\/JABB.2024.172190"},{"key":"e_1_3_3_17_2","unstructured":"AVASTIN (bevacizumab) for intravenous use [package insert]. South San Francisco CA: Genentech Inc. September 18 2022. Accessed March 13 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125085s340lbl.pdf"},{"key":"e_1_3_3_18_2","unstructured":"EYLEA (aflibercept) injection for intravitreal use [package insert]. Tarrytown NY: Regeneron Pharmaceuticals Inc. December 14 2023. Accessed March 13 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125387s087lbl.pdf"},{"key":"e_1_3_3_19_2","unstructured":"VABYSMO (faricimab-svoa) injection for intravitreal use [package insert]. South San Francisco CA: Genentech Inc. July 3 2024. Accessed March 13 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761235s005lbl.pdf"},{"key":"e_1_3_3_20_2","unstructured":"LUCENTIS (ranibizumab injection) for intravitreal injection [package insert]. South San Francisco CA: Genentech Inc."},{"key":"e_1_3_3_21_2","unstructured":"Tetracaine [package insert]. Fort Worth TX: Alcon Laboratories Inc."},{"key":"e_1_3_3_22_2","unstructured":"Tropicamide 1% and Phenylephrine HCL 2.5% [package insert]. Nashville TN: Imprimis Rx."},{"key":"e_1_3_3_23_2","unstructured":"Betadine 5% [package insert]. Fort Worth TX: Alcon Laboratories Inc."},{"key":"e_1_3_3_24_2","unstructured":"Alcon Medical Information: CASE-005841. March 4 2025."},{"key":"e_1_3_3_25_2","unstructured":"2% Lidocaine HCl Injection [package insert]. Lake Forest IL: Hospira Inc."}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251400700","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251400700","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251400700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:57Z","timestamp":1790695497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251400700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/24741264251400700"],"URL":"https:\/\/doi.org\/10.1177\/24741264251400700","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}